Why Keryx Biopharmaceuticals (KERX) Stock Is Down Today

NEW YORK (TheStreet) -- Keryx Biopharmaceuticals (KERX) shares are plummeting, down -13.5% to $12.30, on Thursday after the company posted a net loss more than 10 cents per share worse than it reported last year.

The biotech company posted a net loss of $13.5 million, or -15 cents per share, missing analysts estimates by 7 cents. The company reported a net loss of -2 cents and $2.1 million during the same period last year.

Must Read: Warren Buffett's 10 Favorite Growth Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.


KERX Chart

KERX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar